| |
| |
|
| Insider
Information: |
Foletta Mark G |
| Relationship: |
EVP & Chief Financial ... |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
110,179 |
|
|
Indirect Shares
|
62,398 |
|
|
| Direct
Value |
$1,139,767 |
|
|
|
Indirect Value
|
$7,947,633 |
|
|
| Total
Shares |
172,577 |
|
|
| Total
Value |
$9,087,400 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
1
|
|
Stock
price went up :
|
1
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
| Percentage
Gain/Loss : |
 0.7%
|
13.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amylin Pharmaceuticals Inc |
AMLN |
SVP, Chief Financial O... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
DexCom Inc |
DXCM |
Director |
2024-05-22 |
2,973 |
2024-05-22 |
62,398 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director |
2017-12-04 |
81,910 |
2015-08-13 |
0 |
Premium* |
|
|
AMN Healthcare Services Inc |
AHS |
Director |
2024-04-19 |
10,254 |
2016-04-20 |
0 |
Premium* |
|
|
Forte Biosciences Inc |
FBRX |
EVP & Chief Financial ... |
2019-05-28 |
15,042 |
2017-04-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
• – – |
2012-08-08 |
4 |
D |
$31.00 |
$2,274,470 |
D/D |
(73,370) |
64,702 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$64,000 |
D/D |
71,910 |
81,910 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
• – – |
2012-08-08 |
4 |
D |
$31.00 |
$2,005,762 |
D/D |
(64,702) |
0 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
• – – |
2012-08-08 |
4 |
A |
$31.00 |
$2,005,762 |
D/D |
64,702 |
138,072 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
• – – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
41,457 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
• – – |
2012-08-08 |
4 |
D |
$31.00 |
$370,531 |
I/I |
(11,953) |
0 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
• – – |
2012-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
72,490 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2015-08-13 |
4 |
B |
$7.64 |
$76,405 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
• – – |
2012-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
57,687 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
• – – |
2012-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
49,687 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2014-11-17 |
4 |
A |
$0.00 |
$7 |
D/D |
7,322 |
7,322 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
• – – |
2007-05-31 |
4 |
OE |
$13.25 |
$86,125 |
D/D |
6,500 |
29,742 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
• – – |
2007-05-31 |
4 |
AS |
$45.79 |
$297,663 |
D/D |
(6,500) |
23,242 |
0 |
- |
|
| AHS |
AMN Healthcare Services I... |
Director |
– • – |
2023-04-11 |
4 |
AS |
$84.29 |
$509,638 |
D/D |
(6,042) |
8,073 |
0 |
% |
|
| AHS |
AMN Healthcare Services I... |
Director |
– • – |
2016-04-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,532 |
5,532 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2016-05-25 |
4 |
A |
$0.00 |
$5 |
D/D |
5,450 |
17,443 |
0 |
- |
|
| FBRX |
Forte Biosciences Inc |
EVP & Chief Financial Officer |
• – – |
2017-04-19 |
4 |
B |
$10.00 |
$50,000 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| FBRX |
Forte Biosciences Inc |
EVP & Chief Financial Officer |
• – – |
2019-05-28 |
4 |
B |
$4.30 |
$21,475 |
D/D |
5,000 |
15,042 |
2.74 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$5 |
D/D |
4,952 |
20,595 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2015-06-03 |
4 |
A |
$0.00 |
$5 |
D/D |
4,671 |
11,993 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2023-05-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,488 |
3,306 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2023-05-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,488 |
59,092 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
VP Finance & CFO |
• – – |
2005-10-05 |
4 |
OE |
$5.73 |
$25,069 |
D/D |
4,375 |
27,202 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2018-05-31 |
4 |
A |
$0.00 |
$4 |
D/D |
4,062 |
9,014 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2018-06-01 |
4/A |
A |
$0.00 |
$4 |
D/D |
4,052 |
4,052 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
